Hands On Therapy, Inc | |
3065 College Rd, Fairbanks, AK 99709-3702 | |
(907) 699-3160 | |
(079) 374-1659 |
Full Name | Hands On Therapy, Inc |
---|---|
Type | Facility |
Speciality | Clinic/center - Rehabilitation |
Location | 3065 College Rd, Fairbanks, Alaska |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1245596162 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 2089 (Alaska) | Secondary |
261QR0400X | Clinic/center - Rehabilitation | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Hands On Therapy, Inc 3065 College Rd, Fairbanks, AK 99709-3702 Ph: (907) 374-1686 | Hands On Therapy, Inc 3065 College Rd, Fairbanks, AK 99709-3702 Ph: (907) 699-3160 |
News Archive
The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular testing professionals and leading education initiatives, discussions, and policy actions central to improving the development and application of molecular diagnostics, today reaffirmed its position that the vast majority of laboratory developed tests (LDTs), or laboratory developed procedures (LDPs)—a term coined by AMP to more appropriately capture the nature of these processes as medical services—should continue operating under the regulation of the Clinical Laboratory Improvement Amendments program at the Centers for Medicare & Medicaid Services, and not be subject to pre-market review by the U.S. Food and Drug Administration, as suggested in the draft guidance notification issued to Congress on July 31, 2014.
As hospitals look for ways to stem the opioid crisis, a survey of health-system pharmacy directors released today found that most large health systems have active stewardship programs to prevent the misuse of opioids - with pharmacists playing a key role in detecting drug diversion and identifying strategies to encourage appropriate opioid prescribing.
Though President Barack Obama did not say exactly how screening procedures would change, the director of the Centers for Disease Control and Prevention said officials would consider a variety of options.
Public anxiety about spending and a proposed public health insurance plan, routine distractions like Henry Lewis Gates Jr.'s arrest, and delays in rebutting Republican's attacks are triggering speculation that President Obama may be loosing his groove when it comes to his famous message discipline, the Boston Globe reports.
The U.S. Food and Drug Administration today approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage (metastatic) breast cancer.
› Verified 4 days ago